Citadel Advisors
IMVT icon

Citadel Advisors’s Immunovant IMVT Stock Holding History

Citadel Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$440K Sell
17,700
-79,500
-82% -$2.06M ﹤0.01% 9606
2025
Q4 		$2.47M Buy
97,200
+23,600
+32% +$526K ﹤0.01% 5528
2025
Q3 		$1.19M Buy
73,600
+5,600
+8% +$90.7K ﹤0.01% 7165
2025
Q2 		$1.09M Sell
68,000
-13,600
-17% -$206K ﹤0.01% 6913
2025
Q1 		$1.39M Sell
81,600
-41,300
-34% -$864K ﹤0.01% 6230
2024
Q4 		$3.04M Buy
122,900
+37,200
+43% +$1.06M ﹤0.01% 4810
2024
Q3 		$2.44M Buy
85,700
+11,300
+15% +$333K ﹤0.01% 5150
2024
Q2 		$1.96M Sell
74,400
-5,900
-7% -$168K ﹤0.01% 5349
2024
Q1 		$2.59M Sell
80,300
-126,000
-61% -$4.6M ﹤0.01% 5030
2023
Q4 		$8.69M Sell
206,300
-67,000
-25% -$2.47M ﹤0.01% 3037
2023
Q3 		$10.5M Buy
273,300
+161,400
+144% +$3.65M ﹤0.01% 2632
2023
Q2 		$2.12M Sell
111,900
-18,900
-14% -$352K ﹤0.01% 5052
2023
Q1 		$2.03M Sell
130,800
-62,700
-32% -$1.09M ﹤0.01% 5340
2022
Q4 		$3.43M Buy
193,500
+62,300
+47% +$784K ﹤0.01% 4527
2022
Q3 		$732K Sell
131,200
-97,700
-43% -$478K ﹤0.01% 7670
2022
Q2 		$893K Sell
228,900
-2,000
-0.9% -$8.64K ﹤0.01% 7282
2022
Q1 		$1.27M Sell
230,900
-170,200
-42% -$1.06M ﹤0.01% 7140
2021
Q4 		$3.42M Sell
401,100
-372,500
-48% -$3.08M ﹤0.01% 5088
2021
Q3 		$6.72M Sell
773,600
-108,700
-12% -$981K ﹤0.01% 3751
2021
Q2 		$9.33M Buy
882,300
+687,700
+353% +$9.6M ﹤0.01% 3189
2021
Q1 		$3.12M Buy
+194,600
New +$5.13M ﹤0.01% 5350

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Citadel Advisors's IMVT Position: Q1 2026 in Review

Citadel Advisors reduced its Immunovant (IMVT) stake by 6.5% in Q1 2026, selling an estimated $262K and leaving 144,398 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4918.

Citadel Advisors first reported a position in IMVT in Q1 2020 and has held it in 25 quarters since. The position peaked at $35.5M in Q4 2020. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Citadel Advisors held 144,398 shares of Immunovant worth $3.59M as of Q1 2026.
  • Citadel Advisors sold 10,109 Immunovant shares in Q1 2026, an estimated $262K.
  • Immunovant made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4918 holding.
  • Citadel Advisors first reported a position in Immunovant in Q1 2020 and has held it in 25 quarters since.
  • Citadel Advisors's Immunovant position peaked at $35.5M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.